Addendum to clinical guideline 81, advanced breast cancer
Examining discordance between primary and recurrent breast cancer in terms of oestrogen 7 receptor (ER), human epidermal growth factor receptor 2 (HER-2) and progesterone receptor 8 (PR) status. The 2 studies found there could be discordance in receptor status between the 9 primary tumour and metast...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
[London]
National Institute for Health and Care Excellence
2017, August 2017
|
| Edition: | Final |
| Series: | Clinical guideline addendum: methods, evidence and recommendations
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Examining discordance between primary and recurrent breast cancer in terms of oestrogen 7 receptor (ER), human epidermal growth factor receptor 2 (HER-2) and progesterone receptor 8 (PR) status. The 2 studies found there could be discordance in receptor status between the 9 primary tumour and metastases, which led to altered management in 14.2-20% of cases. Current recommendations in the clinical guideline state that, if disease recurs, further biopsy just to reassess ER and HER-2 status should not be done. This area should therefore be reviewed to see if the clinical guideline needs to be updated in light of the new evidence |
|---|---|
| Physical Description: | 1 PDF file (216 pages) illustrations |